Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family

Cancer Research

Volumn 72, Issue 22, 2012, Pages 5945-5955

  Pouliot, Lynn M ^a,b   Chen, Yu Chi ^c   Bai, Jennifer ^b   Guha, Rajarshi ^c   Martin, Scott E ^c   Gottesman, Michael M ^b   Hall, Matthew D ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CISPLATIN; MICRORNA; MICRORNA 15; MICRORNA 155; MICRORNA 16; MICRORNA 195; MICRORNA 424; MICRORNA 497; PROTEIN KINASE; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WEE1 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CELL CYCLE REGULATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RNA INTERFERENCE; SENSITIVITY ANALYSIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICRORNAS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84869216065     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1400     Document Type: Article

References (43)

1. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
2. Eastman A. The mechanism of action of cisplatin: from adducts to apoptosis. In:Lippert B, editor. Cisplatin: chemistry and biochemistry of a leading anticancer drug. Zurich, Switzerland: Verlag Helvetica Chimica Acta; 1999. p. 111-34.
3. Gottesman MM, Hall MD, Liang XJ, Shen DW. Resistance to cisplatin results from multiple mechanisms in cancer cells. In:Bonetti A, Muggia FM, Leone R, Howell SB, editors. Platinum and other heavy metal compounds in cancer chemotherapy.New York: Humana Press; 2009. p. 83-8.
4. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008;48:495-535.
5. Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 2009;30:546-56.
6. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 2012;64:706-21.
7. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008;98:523-8.
8. Yang X, Fraser M, Moll UM, Basak A, Tsang BK. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006;66:3126-36.
9. Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids 2010;2010:201367.
10. Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 2010;5:186-91.
11. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)- induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-8.
12. Dai Y, Grant S. Methods to study cancer therapeutic drugs that target cell cycle checkpoints. Methods Mol Biol 2011;782:257-304.
13. Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 2008;13:259-71.
14. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK- 1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514-22.
15. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009;8:2992-3000.
16. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 2007;67:6325-32.
17. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001;7:2168-81.
18. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995;55:1982-8.
19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
20. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007;23:175- 205.
21. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14.
22. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102:13944-9.
23. Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer 2010;9:317.
24. Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao G, Nelson PT. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol 2010;402:491-509.
25. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010;17:523-31.
26. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008;111:478-86.
27. Liang XJ, Shen DW, Garfield S, Gottesman MM. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res 2003;63:5909-16.
28. Shen D, Pastan I, Gottesman MM. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 1998;58:268-75.
29. Shen DW, Liang XJ, Gawinowicz MA, Gottesman MM. Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol Pharmacol 2004;66:789-93.
30. Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer 2004;91:270-6.
31. Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, Volinia S, et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A 2011;108:4908-13.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402-8.
33. Pekarsky Y, Zanesi N, Croce CM. Molecular basis of CLL. Semin Cancer Biol 2010;20:370-6.
34. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or downregulated in non-small cell lung cancer. Cancer Res 2009;69:5553-9.
35. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008;14:1271-7.
36. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008;123:372-9.
37. Nijwening JH, Kuiken HJ, Beijersbergen RL. Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes. Cell Cycle 2011;10:380-6.
38. Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, Tibes R, et al. RNAi screening of the kinome identi fies modulators of cisplatin response in ovarian cancer cells. Gynecol Oncol 2010;118:220-7.
39. Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther 2012;11:427-38.
40. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007;13:1955-60.
41. Ashwell S, Zabludoff S. DNA damage detection and repair pathways- recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008;14:4032-7.
42. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
43. Kellogg DR. Wee1-dependent mechanisms required for coordination of cell growth and cell division. J Cell Sci 2003;116:4883-90.